Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Keith T. Flaherty

Division of Hematology/Oncology

Massuchusetts General Hospital Cancer Center

Boston

Massachusetts

USA

[email]@aol.com

Name/email consistency: high

[Claim this account]

Affiliations

Division of Hematology/Oncology, Massuchusetts General Hospital Cancer Center, Boston, Massachusetts, USA. 2010
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA. 2004 - 2009
University of Pennsylvania, Abramson Cancer Center, PA 19104, USA. 2001 - 2009

References

BRAF, a target in melanoma: implications for solid tumor drug development. Flaherty, K.T., McArthur, G. Cancer (2010) [Pubmed]
Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma? Flaherty, K.T., Sun, W. Nat. Clin. Pract. Oncol (2009) [Pubmed]
The future of tyrosine kinase inhibitors: single agent or combination? Flaherty, K.T. Curr. Oncol. Rep (2008) [Pubmed]
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Flaherty, K.T., Schiller, J., Schuchter, L.M., Liu, G., Tuveson, D.A., Redlinger, M., Lathia, C., Xia, C., Petrenciuc, O., Hingorani, S.R., Jacobetz, M.A., Van Belle, P.A., Elder, D., Brose, M.S., Weber, B.L., Albertini, M.R., O'Dwyer, P.J. Clin. Cancer Res. (2008) [Pubmed]
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Flaherty, K.T., Rosen, M.A., Heitjan, D.F., Gallagher, M.L., Schwartz, B., Schnall, M.D., O'Dwyer, P.J. Cancer Biol. Ther. (2008) [Pubmed]
Sorafenib: delivering a targeted drug to the right targets. Flaherty, K.T. Expert. Rev. Anticancer. Ther (2007) [Pubmed]
Sorafenib in renal cell carcinoma. Flaherty, K.T. Clin. Cancer Res. (2007) [Pubmed]
Chemotherapy and targeted therapy combinations in advanced melanoma. Flaherty, K.T. Clin. Cancer Res. (2006) [Pubmed]
New molecular targets in melanoma. Flaherty, K.T. Curr. Opin. Oncol (2004) [Pubmed]
A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine. Flaherty, K.T., Stevenson, J.P., Redlinger, M., Algazy, K.M., Giatonio, B., O'Dwyer, P.J. Cancer Chemother. Pharmacol. (2004) [Pubmed]
Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer. Flaherty, K.T., Stevenson, J.P., Gallagher, M., Giantonio, B., Algazy, K.M., Sun, W., Haller, D.G., O'Dwyer, P.J. Cancer (2003) [Pubmed]
Antisense therapeutics: lessons from early clinical trials. Flaherty, K.T., Stevenson, J.P., O'Dwyer, P.J. Curr. Opin. Oncol (2001) [Pubmed]

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.